AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23681836 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 18
Study 22962205 — intervention group
Group type: EXPERIMENTAL
Intervention: Project P.A.T.H.S. (Tier 1 Program)
Number of subjects: 4049
Study 19374293 — intervention group
Group type: EXPERIMENTAL
Intervention: Placental cord drainage
Number of subjects: 100
Study 19374293 — intervention group
Group type: COMPARATOR
Intervention: Control group (no placental cord drainage)
Number of subjects: 100
Study 19374293 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 17292646 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline
Number of subjects: 20
Study 17292646 — intervention group
Group type: EXPERIMENTAL
Intervention: s.c. terbutaline
Number of subjects: 20
Study 17292646 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 20
Study 15723746 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean System 7 (commercial weight-loss product), 3 capsules twice daily for 8 weeks
Number of subjects: 47
Study 15723746 — intervention group
Group type: COMPARATOR
Intervention: Placebo, identical capsules twice daily for 8 weeks
Number of subjects: 47
Study 11879161 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch from sertraline to imipramine (mean dosage, 221 mg/d)
Number of subjects: 168
Study 11879161 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch from imipramine to sertraline (mean dosage, 163 mg/d)
Number of subjects: 168
Study 11879161 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline treatment
Number of subjects: 168
Study 11879161 — intervention group
Group type: COMPARATOR
Intervention: Imipramine treatment
Number of subjects: 168
Study 11879161 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching treatments
Number of subjects: 168
Study 11879161 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized estimating equation analyses
Number of subjects: 168
Study 10557525 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified brochure with relatively concrete text and abstract graphics
Number of subjects: 239
Study 10557525 — intervention group
Group type: EXPERIMENTAL
Intervention: Relatively concrete text brochure with concrete graphics
Number of subjects: 239
Study 10557525 — intervention group
Group type: EXPERIMENTAL
Intervention: Original brochure containing abstract text and abstract graphics
Number of subjects: 239
Study 10557525 — intervention group
Group type: COMPARATOR
Intervention: Control group (no brochure)
Number of subjects: 239
Study 7798653 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated varicella vaccine (1 dose for children, 2 doses for adults)
Number of subjects: 59
Study 7798653 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated varicella vaccine (2 doses for adults)
Number of subjects: 59
Study 2157637 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrogastrone five tablets daily
Number of subjects: 80
Study 2157637 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 400 mg twice daily
Number of subjects: 80
Study 397016 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidoflazine (120 mg t.i.d. for 9 weeks)
Number of subjects: 28
Study 397016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 31504101 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ-LNS with exogenous phytase
Number of subjects: 30
Study 31504101 — intervention group
Group type: COMPARATOR
Intervention: SQ-LNS without exogenous phytase
Number of subjects: 30
Study 28984580 — intervention group
Group type: EXPERIMENTAL
Intervention: McNair and Kahn Scale
Number of subjects: 1307
Study 28984580 — intervention group
Group type: EXPERIMENTAL
Intervention: McNair and Kahn Scale (5-item version)
Number of subjects: 1307
Study 28984580 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of aggravation score of CDR
Number of subjects: 1307
Study 24975503 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day workshop training for oncologists
Number of subjects: 62
Study 24975503 — intervention group
Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 62
Study 23604626 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous audiovisual stimuli
Number of subjects: 0
Study 23604626 — intervention group
Group type: COMPARATOR
Intervention: Asynchronous audiovisual stimuli
Number of subjects: 0
Study 23604626 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimodal cuing
Number of subjects: 0
Study 23604626 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective judgment of simultaneity
Number of subjects: 0
Study 21484237 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg of hydrocortisone (two boluses of 60 mg)
Number of subjects: 16
Study 21484237 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of dexamethasone (DEX)
Number of subjects: 16
Study 21484237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 19057376 — intervention group
Group type: EXPERIMENTAL
Intervention: Conivaptan 40 mg/d
Number of subjects: 83
Study 19057376 — intervention group
Group type: EXPERIMENTAL
Intervention: Conivaptan 80 mg/d
Number of subjects: 83
Study 19057376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 17715647 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnidirectional microphone processing mode
Number of subjects: 2
Study 17715647 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional microphone processing mode
Number of subjects: 2
Study 17715647 — intervention group
Group type: COMPARATOR
Intervention: Environmental recordings presented in laboratory setting
Number of subjects: 2
Study 15076259 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmotic, controlled-release oral system (OROS) MPH (Concerta) given once daily (q.d.)
Number of subjects: 6
Study 15076259 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release MPH (Ritalin) given in equal doses three times daily (t.i.d.)
Number of subjects: 6
Study 11302799 — intervention group
Group type: EXPERIMENTAL
Intervention: +Calanolide A (200 mg)
Number of subjects: 47
Study 11302799 — intervention group
Group type: EXPERIMENTAL
Intervention: +Calanolide A (400 mg)
Number of subjects: 47
Study 11302799 — intervention group
Group type: EXPERIMENTAL
Intervention: +Calanolide A (600 mg)
Number of subjects: 47
Study 11302799 — intervention group
Group type: EXPERIMENTAL
Intervention: +Calanolide A (800 mg)
Number of subjects: 47
Study 9499204 — intervention group
Group type: EXPERIMENTAL
Intervention: PstI polymorphism at the ACE locus in NIDDM patients with diabetic nephropathy (n = 140)
Number of subjects: 220
Study 9499204 — intervention group
Group type: COMPARATOR
Intervention: PstI polymorphism at the ACE locus in normoalbuminuric control subjects (n = 80)
Number of subjects: 220
Study 7880510 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepine agonists (midazolam 2.5 mg or diazepam 5 mg)
Number of subjects: 0
Study 7880510 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental sodium 1 mg/kg
Number of subjects: 0
Study 7880510 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondepolarizing muscle relaxants (atracurium 40 micrograms/kg or metocurine 50 micrograms/kg)
Number of subjects: 0
Study 7880510 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pretreatment)
Number of subjects: 0
Study 3207438 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclotropium bromide (CTB) administered intravenously
Number of subjects: 10
Study 3207438 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine N‐butylbromide (HNB) administered intravenously
Number of subjects: 10
Study 3207438 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 10
Study 3207438 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclotropium bromide (CTB)
Number of subjects: 10
Study 3207438 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine N‐butylbromide (HNB)
Number of subjects: 10
Study 29336700 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein supplement (SPS) 45g (230 Kcal) added to lunch fruit juice
Number of subjects: 107
Study 29336700 — intervention group
Group type: COMPARATOR
Intervention: Control group (fruit juice without SPS)
Number of subjects: 107
Study 28612083 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (tamsulosin 0.2 mg/day and trospium chloride 20 mg twice daily)
Number of subjects: 124
Study 28612083 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (tamsulosin 0.2 mg/day)
Number of subjects: 124
Study 26317858 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain exposure group (prior exposure to the same pain stimulus)
Number of subjects: 62
Study 26317858 — intervention group
Group type: COMPARATOR
Intervention: Touch exposure group (no prior exposure to pain stimulus)
Number of subjects: 62
Study 23343197 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intensive cognitive-linguistic therapy (Group A) - one hour a day for four weeks, starting within two weeks after stroke.
Number of subjects: 150
Study 23343197 — intervention group
Group type: COMPARATOR
Intervention: Deferred regular therapy (Group B) - professional speech and language therapy deferred for four weeks, followed by conventional therapy.
Number of subjects: 150
Study 20435447 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptic treatment
Number of subjects: 232
Study 19085499 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression bandage
Number of subjects: 48
Study 19085499 — intervention group
Group type: COMPARATOR
Intervention: Non-compression bandage
Number of subjects: 48
Study 19085499 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study 16611657 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon gamma-1b (IFN-gamma 1b) administered subcutaneously thrice weekly for 2 years
Number of subjects: 50
Study 16611657 — intervention group
Group type: COMPARATOR
Intervention: Colchicine for 2 years
Number of subjects: 50
Study 16611657 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon gamma-1b (IFN-gamma 1b)
Number of subjects: 50
Study 16611657 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon gamma-1b (IFN-gamma 1b) and Colchicine
Number of subjects: 50
Study 12868555 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan 125 mg/m2 and mitomycin C 5 mg/m2, given every 2 weeks until progression or limiting toxicity.
Number of subjects: 40
Study 11152253 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention sutures (n = 44)
Number of subjects: 95
Study 11152253 — intervention group
Group type: COMPARATOR
Intervention: Conventional mass closure without retention sutures (n = 51)
Number of subjects: 95
Study 9183137 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (1 hour of bright-light therapy plus 2 hours of dawn simulation)
Number of subjects: 28
Study 9183137 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 hour of clear goggles plus 5 minutes of low-intensity dawn simulation)
Number of subjects: 28
Study 9183137 — intervention group
Group type: EXPERIMENTAL
Intervention: Light therapy
Number of subjects: 28
Study 1550435 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 50 micrograms/min of isosorbide dinitrate (ISDN)
Number of subjects: 19
Study 1550435 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous N-acetylcysteine at a dosage of 10 g/24 hours
Number of subjects: 19
Study 1550435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 3902224 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine (2 mg single oral dose)
Number of subjects: 12
Study 30482631 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive group intervention
Number of subjects: 84
Study 30482631 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study 27814706 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led empowerment counselling intervention (two 30-min counselling sessions)
Number of subjects: 504
Study 27814706 — intervention group
Group type: COMPARATOR
Intervention: Enhanced control condition (a referral list)
Number of subjects: 504
Study 27814706 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led empowerment counselling intervention
Number of subjects: 504
Study 25099748 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal sciatic nerve block (SNB)
Number of subjects: 60
Study 25099748 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal sciatic nerve block (SNB)
Number of subjects: 60
Study 25099748 — intervention group
Group type: COMPARATOR
Intervention: No sciatic nerve block (Placebo)
Number of subjects: 60
Study 25099748 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal and distal sciatic nerve block (SNB)
Number of subjects: 60
Study 25099748 — intervention group
Group type: EXPERIMENTAL
Intervention: Popliteal technique (Distal SNB)
Number of subjects: 60
Study 22515528 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based interpersonal psychotherapy (IPT) sessions (12 sessions within 12 to 16 weeks, provided by trained nurses)
Number of subjects: 240
Study 22515528 — intervention group
Group type: COMPARATOR
Intervention: Standard postpartum care
Number of subjects: 240
Study 21207798 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.5% hydrogen peroxide high-adhesion whitening strips
Number of subjects: 44
Study 21207798 — intervention group
Group type: COMPARATOR
Intervention: 6.5% hydrogen peroxide professional whitening strips
Number of subjects: 44
Study 18425248 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride dentifrice (FD)
Number of subjects: 10
Study 18425248 — intervention group
Group type: COMPARATOR
Intervention: Non-fluoride dentifrice (PD)
Number of subjects: 10
Study 15832421 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC group (omeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg)
Number of subjects: 103
Study 15832421 — intervention group
Group type: COMPARATOR
Intervention: OAM group (omeprazole 20 mg, amoxicillin 1000 mg, metronidazole 400 mg)
Number of subjects: 103
Study 15832421 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC group
Number of subjects: 103
Study 15832421 — intervention group
Group type: COMPARATOR
Intervention: OAM group
Number of subjects: 103
Study 12953127 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg/kg/day (single dose) G-CSF
Number of subjects: 28
Study 12953127 — intervention group
Group type: COMPARATOR
Intervention: 2 x 5 microg/kg/day (split dose) G-CSF
Number of subjects: 28
Study 10638992 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 surgery (radical surgery)
Number of subjects: 400
Study 10638992 — intervention group
Group type: COMPARATOR
Intervention: D1 surgery (conventional surgery)
Number of subjects: 400
Study 8650638 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin treatment
Number of subjects: 0
Study 8650638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1389955 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg
Number of subjects: 10
Study 1389955 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg
Number of subjects: 10
Study 6598018 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Lymphoid Irradiation (TLI)
Number of subjects: 32
Study 6598018 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 32
Study 30650624 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional physical activity intervention (twice a week for 10 weeks)
Number of subjects: 746
Study 30650624 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 746
Study 29888845 — intervention group
Group type: EXPERIMENTAL
Intervention: QuinteT Recruitment Intervention (QRI)
Number of subjects: 0
Study 29888845 — intervention group
Group type: COMPARATOR
Intervention: Standard recruitment methods without QRI
Number of subjects: 0
Study 27869410 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training using flexible Thera-band elastic exercise
Number of subjects: 30
Study 27869410 — intervention group
Group type: COMPARATOR
Intervention: Routine exercises in physical education class
Number of subjects: 30
Study 24853262 — intervention group
Group type: EXPERIMENTAL
Intervention: Tan EndoGlide
Number of subjects: 20
Study 24853262 — intervention group
Group type: COMPARATOR
Intervention: EndoSerter
Number of subjects: 20
Study 22768272 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime energy intake of ∼150% of estimated daily energy expenditure
Number of subjects: 14
Study 22768272 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime energy intake of ∼50% of estimated daily energy expenditure
Number of subjects: 14
Study 22768272 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep
Number of subjects: 14
Study 22768272 — intervention group
Group type: COMPARATOR
Intervention: Sleep deprivation (SD) with energy oversupply
Number of subjects: 14
Study 22768272 — intervention group
Group type: COMPARATOR
Intervention: Sleep deprivation (SD)
Number of subjects: 14
Study 20455296 — intervention group
Group type: EXPERIMENTAL
Intervention: New broader framework for evaluating clinical practice
Number of subjects: 0
Study 20455296 — intervention group
Group type: COMPARATOR
Intervention: Current standard for evaluating evidence
Number of subjects: 0
Study 17868007 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release dipyridamole plus aspirin
Number of subjects: 20000
Study 17868007 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 20000
Study 17868007 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan in addition to usual care
Number of subjects: 20000
Study 17868007 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 20000
Study 17868007 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety evaluation
Number of subjects: 20000
Study 11260535 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg nickel
Number of subjects: 30
Study 11260535 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 mg nickel
Number of subjects: 30
Study 11260535 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 30
Study 9030805 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic CPB (37 degrees C, n = 17)
Number of subjects: 34
Study 9030805 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic CPB (28 degrees C, n = 17)
Number of subjects: 34
Study 9030805 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Normothermic and Hypothermic)
Number of subjects: 34
Study 8391064 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus thoracic radiotherapy (TRT)
Number of subjects: 386
Study 8391064 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (CAV)
Number of subjects: 386
Study 8391064 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation chemotherapy (cisplatin and etoposide)
Number of subjects: 386
Study 8391064 — intervention group
Group type: COMPARATOR
Intervention: Observation after CAV
Number of subjects: 386
Study 3555049 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (250 mg orally, twice daily)
Number of subjects: 60
Study 3555049 — intervention group
Group type: COMPARATOR
Intervention: Cinoxacin (500 mg orally, twice daily)
Number of subjects: 60
Study 3555049 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 60
Study 3555049 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin and Cinoxacin
Number of subjects: 60
Study 29872966 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative forced-air warming using BairPaws™ system for at least 30 min
Number of subjects: 200
Study 29872966 — intervention group
Group type: COMPARATOR
Intervention: Warmed blankets on request (Control)
Number of subjects: 200
Study 29872966 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative forced-air warming
Number of subjects: 200
Study 29872966 — intervention group
Group type: COMPARATOR
Intervention: Control group (Warmed blankets)
Number of subjects: 200
Study 27363482 — intervention group
Group type: EXPERIMENTAL
Intervention: Web‐based self‐help for SI
Number of subjects: 236
Study 27363482 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 236
Study 24706369 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency telephone consultations with simulated patients (SPs)
Number of subjects: 137
Study 24706369 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice to call for an ambulance in ETCs
Number of subjects: 137
Study 23453352 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucomannan (GM) combined with low-dose chromium-polynicotinate (CP)
Number of subjects: 120
Study 23453352 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucomannan (GM) combined with low-dose policosanol (PC)
Number of subjects: 120
Study 23453352 — intervention group
Group type: COMPARATOR
Intervention: Glucomannan (GM) with resistant starch (control)
Number of subjects: 120
Study 20636352 — intervention group
Group type: COMPARATOR
Intervention: K-Flexofile instruments and Gates Glidden drills
Number of subjects: 40
Study 20636352 — intervention group
Group type: EXPERIMENTAL
Intervention: V-Taper Ni-Ti rotary and stainless steel hand instruments
Number of subjects: 40
Study 19026310 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose steroids and cyclosporine
Number of subjects: 20
Study 19026310 — intervention group
Group type: COMPARATOR
Intervention: Muromonab-CD3
Number of subjects: 20
Study 16738915 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous chondrocyte implantation (ACI)
Number of subjects: 27
Study 16738915 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfracture technique (MFR)
Number of subjects: 27
Study 16738915 — intervention group
Group type: COMPARATOR
Intervention: Normal cartilage
Number of subjects: 27
Study 12523327 — intervention group
Group type: EXPERIMENTAL
Intervention: LCD group
Number of subjects: 44
Study 12523327 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study 11086179 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone 36 mg/m2 on day 1
Number of subjects: 24
Study 11086179 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone 45 mg/m2 on day 1
Number of subjects: 24
Study 11086179 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone 60 mg/m2 on day 1
Number of subjects: 24
Study 11086179 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone 75 mg/m2 on day 1 with cytarabine 500 mg/m2 and etoposide 200 mg/m2
Number of subjects: 24